Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBITDA (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed EBITDA for 13 consecutive years, with -$4.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 89.06% to -$4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.3 million, a 26.74% decrease, with the full-year FY2025 number at -$13.3 million, down 26.74% from a year prior.
  • EBITDA was -$4.7 million for Q4 2025 at Ekso Bionics Holdings, down from -$1.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$1.4 million in Q2 2021 to a low of -$4.7 million in Q4 2025.
  • A 5-year average of -$3.1 million and a median of -$3.2 million in 2021 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 88.31% in 2021; the steepest drop was 183.31% in 2021.
  • Ekso Bionics Holdings' EBITDA stood at -$2.6 million in 2021, then crashed by 55.69% to -$4.1 million in 2022, then increased by 7.56% to -$3.8 million in 2023, then surged by 34.9% to -$2.5 million in 2024, then tumbled by 89.06% to -$4.7 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's EBITDA are -$4.7 million (Q4 2025), -$1.4 million (Q3 2025), and -$3.8 million (Q2 2025).